How to Standardize Audit Risks and Legal Exposure Management Across Global Markets

Context

The management of audit risks and legal exposure in the pharmaceuticals and biotechnology sectors is critical, particularly concerning controlled substances compliance. Regulatory Authorities such as the FDA, EMA, and MHRA impose stringent regulations to control substances that pose potential risks to public health. Understanding and adhering to these regulations is essential for Regulatory Affairs (RA), Chemistry, Manufacturing and Controls (CMC), and Labelling teams within pharmaceutical companies operating in the US, EU, and UK. Failure to comply may result in legal repercussions, approval delays, and possible sanctions, emphasizing the need for a comprehensive approach to audit risks and legal exposure management.

Legal/Regulatory Basis

At the core of controlled substances compliance are several key regulatory frameworks and guidelines:

• Controlled Substances Act (CSA): In the United States, this act regulates the manufacture, distribution, and dispensing of controlled substances. Compliance with this legislation is overseen by the Drug Enforcement Administration (DEA).
• EU Regulations on Drug Substances: The EU operates under various directives and regulations including 2001/83/EC which pertains to medicinal products for human use, and Commission Delegated Regulation (EU) 2017/1572 that provides specific provisions regarding controlled substances.
• UK Regulations: Post-Brexit, the UK continues to follow the Misuse of Drugs Regulations 2001, along with other relevant legislation, which parallels EU frameworks to an extent but must be monitored for divergence.
• International Guidelines: The ICH guidelines, particularly ICH Q7 on Good Manufacturing Practice for Active Pharmaceutical Ingredients, provide a framework relevant to the management of audit risks and legal exposure in the context of active ingredients of controlled substances.

Documentation

Robust documentation is foundational for compliance and audit defense. Relevant documentation includes:

1. Substance Schedules: Clearly classify all substances according to their schedule of control, providing the necessary legal classification for different jurisdictions.
2. Risk Assessment Reports: Document assessments identifying potential risks associated with each controlled substance and the current state of compliance.
3. Standard Operating Procedures (SOPs): Create and maintain SOPs that govern the handling, storage, and distribution of controlled substances.
4. Training Records: Keep records of employee training programs related to controlled substances compliance to demonstrate awareness and adherence to protocols.
5. Audit Reports: Regular internal audits must be documented, detailing findings and actions taken to rectify deficiencies.

Review/Approval Flow

The review and approval process for controlled substances requires several key steps and interactions between departments:

• Initial Classification: Determine the legal classification of substances at the development stage, utilizing both internal and external regulatory intelligence to ensure correct scheduling under the CSA, EU regulations, and UK laws.
• CMC Input: Collaborate with the CMC team to ensure that the manufacturing process is compliant with GMP standards and documentation requirements for controlled substances.
• Clinical & Preclinical Review: Legal implications must be evaluated during clinical trial applications to ensure that all controlled substances used in research are compliant.
• Regulatory Submission: The documentation must be assembled for submission to the relevant authorities, ensuring that all regulatory requirements concerning controlled substances are met.
• Post-approval Monitoring: Engage in ongoing oversight to ensure continued compliance and maintain records in anticipation of potential audits.

Audit Risks and Legal Exposure Management

Audit risks and legal exposure management for controlled substances requires a comprehensive strategy. This section discusses practical tips to mitigate risks and ensure compliance:

1. Understanding Audit Risks

Audit risks include the possibility of non-compliance findings during inspections conducted by regulatory authorities. Key areas of concern include:

• Record Keeping: The need for accurate and timely documentation of all actions related to controlled substances.
• Internal Compliance Checks: Regular audits and self-inspections to identify and address potential non-compliances before an external audit.
• Supply Chain Risks: Ensuring that suppliers and distributors comply with controlled substances regulations to minimize potential liabilities.

2. Implementing Security Controls

Security controls are vital in managing legal exposures associated with controlled substances. Recommendations include:

• Access Controls: Limit access to controlled substances to trained personnel only, and maintain a log of access to facilities that handle these substances.
• Surveillance: Implement monitoring systems to detect unauthorized access and ensure that controlled substances are securely stored.
• Incident Management: Have policies in place for incident reporting and follow proper protocols in case of a regulatory breach.

3. Development of a Submission Strategy

A strategic approach towards submissions is crucial:

• Pre-submission Meetings: Engage with regulatory agencies in pre-submission meetings to clarify requirements and expectations.
• Clear Justification for Data Requirements: When filing for variations versus new applications, provide adequate justification for the bridging data to meet agency expectations.
• Timely Submissions: Ensure timely preparation and submission of all required documents to avoid approval delays.

4. Ensuring Inspection Readiness

Preparing for inspections should be an ongoing process:

• Regular Mock Audits: Conduct mock audits to prepare for real inspections and identify possible deficiencies in compliance.
• Document Review: Continuously review and update all documentation to ensure it is accurate and complete before inspections.
• Training Programs: Provide continuous training for all staff involved in handling controlled substances to ensure they are well-versed in compliance requirements.

Common Deficiencies and Agency Expectations

Regulatory agencies have specific expectations regarding compliance with controlled substances regulations. Common deficiencies noted during inspections include:

• Inadequate Documentation: Insufficient record-keeping of inventory, uses, and disposal of controlled substances is one of the top deficiencies.
• Failure to Train Staff: Regulatory bodies expect companies to provide thorough training for staff handling controlled substances.
• Poor Risk Management Practices: Lack of a robust risk assessment process for controlled substances can result in non-compliance findings.
• Supply Chain Violations: Non-compliance from suppliers or distributors can lead to significant legal and regulatory exposure.

Conclusion

Audit risks and legal exposure management regarding controlled substances compliance is a multifaceted challenge that requires diligent attention across various domains within a pharmaceutical company. By understanding the relevant regulations, maintaining robust documentation, implementing stringent security controls, and undertaking proactive strategies for submissions and inspections, Regulatory Affairs and related teams can mitigate risks effectively and ensure compliance with agencies like the FDA, EMA, and MHRA.

For detailed guidance on compliance and best practices, reference FDA’s Controlled Substances Act, EMA Controlled Substances Guidelines, and ICH Quality Guidelines.